Read on Twitter
These are the #HCM sessions and abstracts (original research) I am looking forward to @ #ACC21 - add the ones I missed
First - an important analysis from the EXPLORER-HCM trial - Health status and patient-reported outcomes
#Cardiotwitter
First - an important analysis from the EXPLORER-HCM trial - Health status and patient-reported outcomes
#Cardiotwitter
An interim analysis of effect of mavacamten in MAVA-LTE (EXPLORER-HCM open label extension study).
Aside from gradient reduction, preserved LVEF on average and impressive NTproBNP reduction.
Aside from gradient reduction, preserved LVEF on average and impressive NTproBNP reduction.
Important pre-clinical data using the HCM mini pig model - where treatment with a mavacamten surrogate (MYK-581) improved myocardial glucose metabolism, prevented LV fibrosis, and reduced cardiac troponin leakage (i.e. less myocyte injury)
From our group with @OHSUCardFellow @OHSUCardio fellow Paola Roldan under the mentorship on @JLindnerMD
Improved prediction of G+ patients
Outcomes of post-myectomy AF - received more anticoagulation, more AF in the future, no association with stroke (many were treated already with AC).
More data on CPET in oHCM
Important work from the Yale group showing how mavacamten reduces diastolic stuffiness and isovolumetric relaxation time - holding promise in not just treating hypercontractility of #HCM
Phenylephrine use to predict who needs concomitant mitral intervention during myectomy
Clinical data on HCM using a commercial database
Wide variation in metoprolol plasma concentration in HCM
Detecting #HCM by applying an AI-ECG algorithm
On T2 mapping in HCM
Not original research but an exciting sessions with hot debates
